了解老年住院患者的手握措施:与虚弱,日常功能和疲劳的关联
Geeske Peeters1,2, Myrthe M Swart3, Liza De Dobbeleer4
1Department of Geriatric Medicine, Radboud university medical centre, Nijmegen, The Netherlands. geeske.peeters@radboudumc.nl.
Aging clinical and experimental research
|October 11, 2025
概括
握力强度 (GSmax) 和能力与感知活力比率 (CPV) 等手握力指标显示,对老年患者的脆弱性进行评估具有前景. 疲劳耐力 (FR) 和握力 (GW) 也可能表明功能限制和恢复潜力.
科学领域:
- 老年医学 老年医学
- 康复科学 康复科学 康复科学
- 生物医学工程 生物医学工程
背景情况:
- 手握测量正在成为评估老年患者康复的有价值指标.
- 了解通过握力和相关指标测量的特定结构对于临床解释至关重要.
研究的目的:
- 澄清各种手握措施 (握力,耐疲劳,握力,能力与感知活力比率) 与老年患者的虚弱,功能限制和疲劳指标之间的关联.
- 探索抓地尺寸的替代操作定义,以提高其可解释性和可靠性.
主要方法:
- 181名老年住院患者每天两次使用活力计进行握力测量,以捕捉最大握力 (GSmax),疲劳阻力 (FR),握力工作 (GW) 和感知活力比率 (CPV) 的能力.
- 线性回归分析检查了抓地力测量和对脆弱指数,功能限制和身体疲劳的验证尺度之间的关联.
- 对基线值,初始测量的平均值和握力测量的差异指标 (标准偏差,变化系数) 进行了分析.
主要成果:
- 基线最大握力 (GSmax) 显示出与脆弱性,功能限制和身体疲劳相关的趋势.
- 耐疲劳 (FR),握力 (GW) 和能力与感知活力比率 (CPV) 显示出与功能限制相关的趋势,但与脆弱或整体疲劳无关.
- 与单个测量相比,平均握力测量值和人体内的标准偏差显示了提高可靠性和额外信息的潜力.
结论:
- 最大握力 (GSmax) 和能力与感知活力比率 (CPV) 似乎更强烈地反映了脆弱的结构,而不是疲劳抵抗 (FR) 和握力 (GW).
- 疲劳抵抗力 (FR),握力 (GW) 和能力与感知活力比率 (CPV) 显示出作为老年患者功能恢复的早期指标的潜力.
- 使用平均握力测量值并考虑差异指标可以提高手握力评估的临床实用性,用于监测老年患者的康复.
更多相关视频
05:53Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
Published on: July 24, 2013
17.0K
06:52Assessment of Dependence in Activities of Daily Living Among Older Patients in an Acute Care Unit
Published on: September 30, 2020
10.4K
相关概念视频
Drug Dosing: Geriatric Patients
199
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
199
Pharmacodynamics in Geriatric Patients: Effects of Age
172
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
172
